Loading...
Market
Story
Scholar Rock's Apitegromab Succeeds in Phase 3 SMA Trial with p=0.019, Stock Soars 200%
Oct 7, 2024, 12:01 PM
Scholar Rock announced that its drug apitegromab met the primary endpoint in a Phase 3 SAPPHIRE study for treating spinal muscular atrophy (SMA). The trial, which achieved statistical significance with a p-value of 0.019, demonstrated a clinically meaningful improvement in motor function among patients. As a result, Scholar Rock's stock soared more than 200%. The late-stage study involved patients already on standard-of-care treatments such as Spinraza and Risdiplam. The success of the trial positions Scholar Rock as a potential key player in the SMA treatment market.
View original story
Similar markets
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%
Merger or acquisition • 25%
New major partnership • 25%
Launch of another Phase 3 trial • 25%
Other • 25%
Launch a new drug • 25%
Enter a new partnership • 25%
Expand into new markets • 25%
No major changes • 25%
Increase Bitcoin holdings • 25%
Invest in another cryptocurrency • 25%
Invest in traditional assets • 25%
No major investment move • 25%
Pharmaceutical company • 25%
Government agency • 25%
Research institution • 25%
Other • 25%
Yes • 50%
No • 50%
